Rhythm Pharmaceuticals (RYTM) EVP receives RSUs and 32,500 stock options

Rhea-AI Filing Summary

Rhythm Pharmaceuticals executive Jennifer Kayden Lee received new equity awards tied to her role as EVP, Head of North America. On February 11, 2026, she was granted 21,650 restricted stock units, each representing one share of common stock, and 32,500 stock options with a $98.47 exercise price.

The restricted stock units vest in four equal 25% installments on February 1, 2027, 2028, 2029, and 2030 and have no expiration date. The stock options expire on February 10, 2036 and vest in 16 substantially equal installments, each after three full months of continued service following the grant date. All awards are held directly.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Lee Jennifer Kayden

Role EVP, Head of North America

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	21,650	$0.00	--
Grant/Award	Stock Options (Right to Buy)	32,500	$0.00	--

Holdings After Transaction: Restricted Stock Units — 21,650 shares (Direct); Stock Options (Right to Buy) — 32,500 shares (Direct)

Footnotes (1)

1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date. The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lee Jennifer Kayden

(Last) (First) (Middle)

C/O RHYTHM PHARMACEUTICALS, INC.

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Head of North America

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	02/11/2026		A		21,650		(2)	(2)	Common Stock	21,650	$0	21,650	D
Stock Options (Right to Buy)	$98.47	02/11/2026		A		32,500		(3)	02/10/2036	Common Stock	32,500	$0	32,500	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

2. The restricted stock units vest as to 25% of the total shares on each of February 1, 2027, February 1, 2028, February 1, 2029 and February 1, 2030. The restricted stock units have no expiration date.

3. The stock options were granted on February 11, 2026. The options vest and become exercisable in 16 substantially equal installments upon the Reporting Person's completion of each three full months of successive service to the Issuer following the grant date.

	/s/ Stephen Vander Stoep, Attorney-in-Fact for Jennifer Kayden Lee	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Rhythm Pharmaceuticals (RYTM) report in this Form 4 filing?

Rhythm Pharmaceuticals reported equity awards to executive Jennifer Kayden Lee. She received 21,650 restricted stock units and 32,500 stock options on February 11, 2026, as part of her compensation as EVP, Head of North America, all held as direct ownership.

How many restricted stock units did Rhythm Pharmaceuticals EVP receive?

Executive Jennifer Kayden Lee received 21,650 restricted stock units. Each unit is a contingent right to one share of Rhythm Pharmaceuticals common stock, vesting over four years in equal 25% installments on February 1 of 2027, 2028, 2029, and 2030, with no expiration date.

What stock options were granted in the Rhythm Pharmaceuticals (RYTM) Form 4?

Jennifer Kayden Lee was granted 32,500 stock options with a $98.47 exercise price. These options were granted on February 11, 2026, and become exercisable in 16 substantially equal installments, each after three full months of continuous service, expiring on February 10, 2036.

How do the restricted stock units for Rhythm Pharmaceuticals vest?

The restricted stock units vest as 25% of the total shares on February 1, 2027, 2028, 2029, and 2030. This four-year vesting schedule ties value to continued service and long-term alignment with Rhythm Pharmaceuticals common stock performance.

When do the Rhythm Pharmaceuticals stock options granted to the EVP expire?

The stock options granted to Jennifer Kayden Lee expire on February 10, 2036. Before expiration, they vest in 16 substantially equal installments, each triggered by completing three full months of successive service with Rhythm Pharmaceuticals after the February 11, 2026 grant date.

Is the Rhythm Pharmaceuticals executive equity award a purchase or a grant?

The filing shows grants, not open-market purchases. The Form 4 uses transaction code “A” for both the 21,650 restricted stock units and 32,500 stock options, indicating awards or other acquisitions as part of compensation rather than buy or sell transactions in the market.